Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory
We came across a bullish thesis on Intellia Therapeutics, Inc. on Danny’s Substack by Danny Green.
Intellia Therapeutics Inc. (NTLA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 6,370 | $81,663 | 0.09% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.35 | 150,000 | $1,402,500.00 | 207,453 | 2026-01-05 | Filing | |
| $10.03 | 100,000 | $1,003,000.00 | 134,693 | 2025-08-20 | Filing | |
| $15.50 | 4,250 | $65,875.00 | 7,500 | 2019-03-06 | Filing | |
| $16.00 | 3,250 | $52,000.00 | 3,250 | 2019-03-06 | Filing | |
| $18.00 | 58,534 | $1,053,612.00 | 2,662,180 | 2016-05-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.78 | 1,211 | $16,687.58 | 156,794 | 2026-03-02 | Filing | |
| $13.78 | 607 | $8,364.46 | 93,864 | 2026-03-02 | Filing | |
| $9.21 | 34,146 | $314,484.66 | 1,013,339 | 2026-01-05 | Filing | |
| $9.21 | 8,508 | $78,358.68 | 98,533 | 2026-01-05 | Filing | |
| $9.21 | 10,397 | $95,756.37 | 101,528 | 2026-01-05 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 102,924 | $1,319,486 | 0.36% | |
| 2. | 54,475 | $698,370 | 0.14% | |
| 3. | 25,110 | $321,910 | 0.01% | |
| 4. | 23,058 | $295,604 | 0.02% | |
| 5. | 18,808 | $246,949 | 0% |
News See All
Intellia Therapeutics (NTLA) Announces Fiscal Q4 and Full Year 2025 Financial Results
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the top gene therapy stocks to buy according to hedge funds. Intellia Therapeutics, Inc.
Top 10 Gene Therapy Stocks to Buy According to Hedge Funds
On February 23, Lauren Goodwin, New York Life Investments, appeared on CNBC’s ‘Closing Bell’ to talk about the state of equity markets and tariff uncertainties.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2025 Earnings Call Transcript
Operator: Hello, and welcome to Intellia Therapeutics, Inc.'s fourth quarter and full year 2025 conference call. My name is Drew, and I will be your conference operator today.
H.C. Wainwright Boosts Intellia (NTLA) Price Target After MAGNITUDE-2 Hold Lifted
Intellia Therapeutics, Inc. (NASDAQ:NTLA) ranks among the best innovative stocks to buy according to Wall Street analysts. H.C. Wainwright reiterated a Buy rating on Intellia Therapeutics, Inc.
13 Best Innovative Stocks to Buy According to Wall Street Analysts
Innovation is entering a new phase of rapid acceleration, according to ARK Invest.
Baird Updates Intellia Therapeutics, Inc. (NTLA)'s Financial Model Following Nex-Z Clinical Hold Removal
TheFly reported on January 28 that Baird raised its price target on NTLA to $7 from $4 while maintaining a Neutral rating.
20 Best Biotech Stocks Under $20 to Buy Now
The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.
What Makes Intellia Therapeutics (NTLA) an Interesting Investment?
Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the “Contrarius Global Equity Fund”. A copy of the letter can be downloaded here.
Intellia Therapeutics, Inc. (NTLA): A Bear Case Theory
We came across a bearish thesis on Intellia Therapeutics, Inc. on X.com by A_May_MD. In this article, we will summarize the bulls’ thesis on NTLA.
Hedge Fund Resource Center